What to Look for in COPD Next Year

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.

Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

/ image credit ©alesmunt/stock.adobe.com

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Dupilumab Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study / image courtesy of ResearchGate

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Roche's Investigational Anti-IL-33/ST2 Antibody for COPD Misses Phase 3 Primary Endpoint

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

Related Content

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.

Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.